Case 1:17-cv-00379-LPS Document 1 Filed 04/05/17 Page 1 of 10 PageID #: 1
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`BRISTOL-MYERS SQUIBB COMPANY,
`AND PFIZER INC.,
`
`
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`
`
`
`
`Plaintiffs,
`
`v.
`
`Defendant.
`
`
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`Civil Action No.____
`
`COMPLAINT
`
`Plaintiffs Bristol-Myers Squibb Company (“BMS”) and Pfizer Inc. (“Pfizer”) (BMS and
`
`Pfizer, collectively, “Plaintiffs”), by their attorneys, hereby allege as follows:
`
`NATURE OF THE ACTION
`
`1.
`
`This is an action for patent infringement arising under the patent laws of the United
`
`States, Title 35, United States Code, against Defendant Mylan Pharmaceuticals Inc. (“Mylan”).
`
`This action relates to Abbreviated New Drug Application (“ANDA”) No. 210128 filed by Mylan
`
`with the U.S. Food and Drug Administration (“FDA”).
`
`2.
`
`In ANDA No. 210128, Mylan seeks approval to market 2.5 mg and 5 mg tablets of
`
`apixaban, generic versions of Plaintiffs’ Eliquis® drug product (the “Mylan ANDA product”),
`
`prior to expiration of U.S. Patent Nos. 6,967,208 (the “’208 patent”) and 9,326,945 (the “’945
`
`patent”) (collectively, the “patents-in-suit”).
`
`
`
`

`

`Case 1:17-cv-00379-LPS Document 1 Filed 04/05/17 Page 2 of 10 PageID #: 2
`
`PARTIES
`
`3.
`
`BMS is a corporation organized and existing under the laws of Delaware, having a
`
`place of business at Route 206 and Province Line Road, Princeton, New Jersey 08540.
`
`4.
`
`Pfizer is a corporation organized and existing under the laws of Delaware, having
`
`its principal place of business at 235 East 42nd Street, New York, New York 10017.
`
`5.
`
`Plaintiffs are engaged in the business of creating, developing, and bringing to
`
`market revolutionary pharmaceutical products to help patients prevail against serious diseases,
`
`including treatments for thromboembolic disorders. Plaintiffs sell Eliquis® in this judicial district
`
`and throughout the United States.
`
`6.
`
`Upon information and belief, Mylan is a corporation organized and existing under
`
`the laws of West Virginia, having its principal place of business at 781 Chestnut Ridge Road,
`
`Morgantown, West Virginia 26505.
`
`7.
`
`On information and belief, Mylan is registered to do business in Delaware (File
`
`Number 4809319).
`
`8.
`
`On information and belief, Mylan has designated its registered agent for the receipt
`
`of service of process for the State of Delaware as Corporation Service Company, 2711 Centerville
`
`Road, Suite 400, Wilmington, Delaware 19808.
`
`9.
`
`On information and belief, Mylan is actively registered with the Delaware Board of
`
`Pharmacy, pursuant to 24 Del. C. § 2540, as a licensed “Pharmacy-Wholesale” (License No.
`
`A4-0001719) and “Distributor/Manufacturer CSR” (License No. DM-00007571).
`
`10.
`
`On information and belief, Mylan is in the business of making and selling generic
`
`pharmaceutical products, which it distributes in the State of Delaware and throughout the United
`
`States.
`
`
`
`- 2 -
`
`

`

`Case 1:17-cv-00379-LPS Document 1 Filed 04/05/17 Page 3 of 10 PageID #: 3
`
`JURISDICTION AND VENUE
`
`11.
`
`This action arises under the patent laws of the United States, 35 U.S.C. §§ 100, et
`
`seq., and this Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331,
`
`1338(a), 2201, and 2202.
`
`12.
`
`This Court has jurisdiction over Mylan because, inter alia, Mylan has committed
`
`an act of patent infringement under 35 U.S.C. § 271(e)(2) and intends a future course of conduct
`
`that includes acts of patent infringement in Delaware. These acts have led and will lead to
`
`foreseeable harm and injury to Plaintiffs, both Delaware corporations, in Delaware. For example,
`
`on information and belief, following approval of ANDA No. 210128, Mylan will make, use,
`
`import, sell, and/or offer for sale the Mylan ANDA product in the United States, including in
`
`Delaware, prior to the expiration of the patents-in-suit.
`
`13.
`
`This Court also has jurisdiction over Mylan because, inter alia, this action arises
`
`from actions of Mylan directed toward Delaware, and because Mylan has purposefully availed
`
`itself of the rights and benefits of Delaware law by engaging in systematic and continuous contacts
`
`with Delaware. Upon information and belief, Mylan is registered to do business in Delaware
`
`(File Number 4809319), is actively registered with the Delaware Board of Pharmacy (License
`
`Nos. A4-0001719 and DM-00007571), and has designated a registered agent for the receipt of
`
`service of process in Delaware. Upon information and belief, Mylan regularly and continuously
`
`transacts business within Delaware, including by selling pharmaceutical products in Delaware.
`
`Upon information and belief, Mylan derives substantial revenue from the sale of those products in
`
`Delaware and has availed itself of the privilege of conducting business within Delaware.
`
`14. Mylan has previously been sued in this judicial district and has availed itself of
`
`Delaware courts through the assertion of claims and counterclaims in suits brought in Delaware
`
`
`
`- 3 -
`
`

`

`Case 1:17-cv-00379-LPS Document 1 Filed 04/05/17 Page 4 of 10 PageID #: 4
`
`including Mylan Pharms. Inc. v. Ethypharm SA, 1-10-cv-01064, and Mylan Pharms. Inc. v.
`
`Galderma Laboratories Inc., 1-10-cv-00892.
`
`15.
`
`Venue is proper in this Court under 28 U.S.C. §§ 1391 and/or 1400(b), including
`
`because, inter alia, Mylan is subject to personal jurisdiction in this district, as set forth above, has
`
`committed an act of infringement and will commit further acts of infringement in this judicial
`
`district, as set forth in more detail in paragraph 12 above, and, upon information and belief, has a
`
`regular and established place of business in this judicial district.
`
`16.
`
`For these reasons, and for other reasons that will be presented to the Court if
`
`jurisdiction and/or venue is challenged, the Court has personal jurisdiction over Mylan, and venue
`
`in this judicial district is proper.
`
`PATENTS-IN-SUIT
`
`17.
`
`On November 22, 2005, the U.S. Patent and Trademark Office duly and legally
`
`issued the ’208 patent, titled “Lactam-Containing Compounds and Derivatives thereof as Factor
`
`Xa Inhibitors.” A true and correct copy of the ’208 patent is attached hereto as Exhibit A. The
`
`claims of the ’208 patent are valid, enforceable, and not expired. BMS is the owner of the ’208
`
`patent and has the right to enforce it.
`
`18.
`
`On May 3, 2016, the U.S. Patent and Trademark Office duly and legally issued the
`
`’945 patent, titled “Apixaban Formulations.” A true and correct copy of the ’945 patent is
`
`attached hereto as Exhibit B. The claims of the ’945 patent are valid, enforceable, and not
`
`expired. Plaintiffs are the joint owners of the ’945 patent and have the right to enforce it.
`
`19.
`
`BMS is the holder of New Drug Application (“NDA”) No. 202155, by which the
`
`FDA granted approval for the marketing and sale of 2.5 mg and 5 mg strength apixaban tablets.
`
`Plaintiffs market apixaban tablets in the United States, under the trade name “Eliquis®.” The
`
`FDA’s official publication of approved drugs (the “Orange Book”) includes Eliquis® together with
`- 4 -
`
`
`
`

`

`Case 1:17-cv-00379-LPS Document 1 Filed 04/05/17 Page 5 of 10 PageID #: 5
`
`the patents-in-suit. Eliquis® is a factor Xa inhibitor indicated: (1) to reduce the risk of stroke and
`
`systemic embolism in patients with nonvalvular atrial fibrillation; (2) for the prophylaxis of deep
`
`vein thrombosis (“DVT”), which may lead to pulmonary embolism (“PE”), in patients who have
`
`undergone hip or knee replacement surgery; and (3) for the treatment of DVT and PE, and for the
`
`reduction in the risk of recurrent DVT and PE following initial therapy. A copy of the complete
`
`prescribing information for Eliquis® approved in NDA No. 202155 is attached as Exhibit C.
`
`INFRINGEMENT BY MYLAN
`
`20.
`
`By letter sent by Federal Express on March 2, 2017, Mylan notified Plaintiffs that
`
`Mylan had submitted ANDA No. 210128 to the FDA under Section 505(j) of the Federal Food,
`
`Drug, and Cosmetic Act (21 U.S.C. § 355(j)) (“the Eliquis Notice Letter”). Plaintiffs received the
`
`Eliquis Notice Letter no earlier than March 3, 2017.
`
`21.
`
`The Eliquis Notice Letter states that Mylan seeks approval from the FDA to engage
`
`in the commercial manufacture, use, and sale of the Mylan ANDA product before the expiration of
`
`the patents-in-suit. Upon information and belief, Mylan intends to – directly or indirectly –
`
`engage in the commercial manufacture, use, and sale of the Mylan ANDA product promptly upon
`
`receiving FDA approval to do so.
`
`22.
`
`By filing ANDA No. 210128, Mylan has necessarily represented to the FDA that
`
`the Mylan ANDA product has the same active ingredient as Eliquis®, has the same dosage form
`
`and strength as Eliquis®, and is bioequivalent to Eliquis®.
`
`23.
`
`Upon information and belief, Mylan is seeking approval to market the Mylan
`
`ANDA product for the same approved indications as Eliquis®.
`
`24.
`
`In the Eliquis Notice Letter, Mylan states that its ANDA contains a certification
`
`pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) asserting that the patents-in-suit are invalid,
`
`
`
`- 5 -
`
`

`

`Case 1:17-cv-00379-LPS Document 1 Filed 04/05/17 Page 6 of 10 PageID #: 6
`
`unenforceable, and/or will not be infringed by the commercial manufacture, use, and sale of the
`
`Mylan ANDA product.
`
`25.
`
`In the Eliquis Notice Letter, Mylan offered confidential access to portions of its
`
`ANDA No. 210128 on terms and conditions set forth in the Eliquis Notice Letter (“the Mylan
`
`Offer”). Mylan requested that Plaintiffs accept the Mylan Offer before receiving access to
`
`Mylan’s ANDA No. 210128. The Mylan Offer contained unreasonable restrictions well beyond
`
`those that would apply under a protective order on who could view the ANDA. The Mylan Offer
`
`unreasonably restricted the ability of counsel to seek the opinions of Plaintiffs’ employees and
`
`outside experts; and Mylan did not provide any means of gaining permission to seek outside expert
`
`access to the Mylan ANDA. The restrictions Mylan has placed on access to ANDA No. 210128
`
`contravene 21 U.S.C. § 355(j)(5)(C)(i)(III), which states that an offer of confidential access “shall
`
`contain such restrictions as to persons entitled to access, and on the use and disposition of any
`
`information accessed, as would apply had a protective order been entered for the purpose of
`
`protecting trade secrets and other confidential business information” (emphasis added).
`
`26.
`
`This Complaint is being filed before the expiration of forty-five days from the date
`
`Plaintiffs received the Eliquis Notice Letter.
`
`COUNT I
`
`(INFRINGEMENT OF THE ’208 PATENT)
`
`27.
`
`Each of the preceding paragraphs 1 to 26 is incorporated as if fully set forth herein.
`
`28. Mylan’s submission of ANDA No. 210128 to obtain approval to engage in the
`
`commercial manufacture, use, offer to sell, or sale of the Mylan ANDA product prior to the
`
`expiration of the ’208 patent constituted a technical act of infringement of at least one of the claims
`
`of the ’208 patent, either literally or under the doctrine of equivalents, including but not limited to
`
`claims 8, 13, 26-27, and 55-61, under 35 U.S.C. § 271(e)(2)(A).
`
`
`
`- 6 -
`
`

`

`Case 1:17-cv-00379-LPS Document 1 Filed 04/05/17 Page 7 of 10 PageID #: 7
`
`29. Mylan’s commercial manufacture, use, offer to sell, sale, or importation of the
`
`Mylan ANDA product prior to the expiration of the ’208 patent, and its inducement of and/or
`
`contribution to such conduct, would further infringe, either literally or under the doctrine of
`
`equivalents, at least one of the claims of the ’208 patent, including but not limited to claims 8, 13,
`
`and 26-27, under 35 U.S.C. §§ 271(a), (b) and/or (c).
`
`30. Mylan’s commercial manufacture, use, offer to sell, sale, or importation of the
`
`Mylan ANDA product for the same treatment claimed in the ’208 patent prior to the expiration of
`
`the ’208 patent, and its inducement of and/or contribution to such conduct, would further infringe,
`
`either literally or under the doctrine of equivalents, at least one of the claims of the ’208 patent,
`
`including but not limited to claims 55-61, under 35 U.S.C. §§ 271(a), (b) and/or (c).
`
`31.
`
`Upon FDA approval of Mylan’s ANDA No. 210128, Mylan will infringe, either
`
`literally or under the doctrine of equivalents, at least one of the claims of the ’208 patent, including
`
`but not limited to claims 8, 13, 26-27, and 55-61, by making, using, offering to sell, and selling the
`
`Mylan ANDA product in the United States and/or importing said product into the United States, or
`
`by actively inducing and contributing to infringement of the ’208 patent by others, under 35 U.S.C.
`
`§ 271(a)-(c), unless enjoined by the Court.
`
`32.
`
`If Mylan’s marketing and sale of the Mylan ANDA product prior to expiration of
`
`the ’208 patent and all other relevant exclusivities are not enjoined, BMS will suffer substantial
`
`and irreparable harm for which there is no remedy at law.
`
`COUNT II
`
`(INFRINGEMENT OF THE ’945 PATENT)
`
`33.
`
`Each of the preceding paragraphs 1 to 32 is incorporated as if fully set forth herein.
`
`34. Mylan’s submission of ANDA No. 210128 to obtain approval to engage in the
`
`commercial manufacture, use, offer to sell, or sale of the Mylan ANDA product prior to the
`
`
`
`- 7 -
`
`

`

`Case 1:17-cv-00379-LPS Document 1 Filed 04/05/17 Page 8 of 10 PageID #: 8
`
`expiration of the ’945 patent constituted a technical act of infringement of at least one of the claims
`
`of the ’945 patent, either literally or under the doctrine of equivalents, including but not limited to
`
`claims 1, 9-12, 20-23, 25, 27, 29, 31, 33, 35, and 37, under 35 U.S.C. § 271(e)(2)(A).
`
`35.
`
`Defendant’s commercial manufacture, use, offer to sell, sale, or importation of the
`
`Mylan ANDA product prior to the expiration of the ’945 patent, and its inducement of and/or
`
`contribution to such conduct, would further infringe at least one of the claims of the ’945 patent,
`
`either literally or under the doctrine of equivalents, including but not limited to claims 1, 9-12,
`
`20-23, 25, 27, 29, 31, 33, 35, and 37, under 35 U.S.C. §§ 271(a), (b) and/or (c).
`
`36.
`
`Upon FDA approval of Mylan’s ANDA No. 210128, Mylan will infringe one or
`
`more claims of the ’945 patent, either literally or under the doctrine of equivalents, including but
`
`not limited to claims 1, 9-12, 20-23, 25, 27, 29, 31, 33, 35, and 37, by making, using, offering to
`
`sell, and selling the Mylan ANDA product in the United States and/or importing said product into
`
`the United States, or by actively inducing and contributing to infringement of the ’945 patent by
`
`others, under 35 U.S.C. § 271(a)-(c), unless enjoined by the Court.
`
`37.
`
`If Defendant’s marketing and sale of the Mylan ANDA product prior to expiration
`
`of the ’945 patent and all other relevant exclusivities are not enjoined, Plaintiffs will suffer
`
`substantial and irreparable harm for which there is no remedy at law.
`
`PRAYER FOR RELIEF
`
`WHEREFORE, Plaintiffs pray that this Court grant the following relief:
`
`1.
`
`A judgment that the claims of the patents-in-suit are not invalid, are not
`
`unenforceable, and are infringed by Mylan’s submission of ANDA No. 210128, either literally or
`
`under the doctrine of equivalents, and that Mylan’s making, using, offering to sell, or selling in the
`
`United States, or importing into the United States the Mylan ANDA product will infringe the
`
`claims of the patents-in-suit, either literally or under the doctrine of equivalents.
`
`
`
`- 8 -
`
`

`

`Case 1:17-cv-00379-LPS Document 1 Filed 04/05/17 Page 9 of 10 PageID #: 9
`
`2.
`
`An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective
`
`date of any approval of ANDA No. 210128 shall be a date which is not earlier than the latest
`
`expiration date of the patents-in-suit, including any extensions and/or additional periods of
`
`exclusivity to which Plaintiffs are or become entitled.
`
`3.
`
`An order permanently enjoining Mylan, its affiliates, subsidiaries, and each
`
`of its officers, agents, servants and employees and those acting in privity or concert with them,
`
`from making, using, offering to sell, or selling in the United States, or importing into the United
`
`States the Mylan ANDA product until after the latest expiration date of the patents-in-suit,
`
`including any extensions and/or additional periods of exclusivity to which Plaintiffs are or become
`
`entitled.
`
`4.
`
`Damages or other monetary relief, including costs, fees, pre and
`
`post-judgment interest, to Plaintiffs if Mylan engages in commercial manufacture, use, offers to
`
`sell, sale, or importation in or into the United States of the Mylan ANDA product prior to the latest
`
`expiration date of the patents-in-suit, including any extensions and/or additional periods of
`
`exclusivity to which Plaintiffs are or become entitled.
`
`5.
`
`Such further and other relief as this Court deems proper and just, including
`
`any appropriate relief under 35 U.S.C. § 285.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`- 9 -
`
`

`

`Case 1:17-cv-00379-LPS Document 1 Filed 04/05/17 Page 10 of 10 PageID #: 10
`
`Dated: April 5, 2017
`
`Of Counsel:
`
`Amy K. Wigmore
`Gregory H. Lantier
`Tracey C. Allen
`Heather M. Petruzzi
`Jeffrey T. Hantson
`Wilmer Cutler Pickering Hale and Dorr LLP
`1875 Pennsylvania Ave, NW
`Washington, DC 20006
`202-663-6000
`202-663-6363
`
`
`
`
`
`
`
`Respectfully submitted,
`
`FARNAN LLP
`
`
`
`/s/ Michael J. Farnan
`Joseph J. Farnan, Jr. (Bar No. 100245)
`Brian E. Farnan (Bar No. 4089)
`Michael J. Farnan (Bar No. 5165)
`919 N. Market Str., 12th Floor
`Wilmington, DE 19801
`Tel: (302) 777-0300
`Fax: (302) 777-0301
`farnan@farnanlaw.com
`bfarnan@farnanlaw.com
`mfarnan@farnanlaw.com
`
`Counsel for Plaintiffs Bristol-Myers Squibb
`Company and Pfizer Inc.
`
`
`- 10 -
`
`